7,502.44

-47.50

-0.63%

52,086.87

-302.88

-0.58%

25,036.96

-216.18

-0.86%

2,803.74

-37.07

-1.30%

4.9940

+0.1300

+2.67%

20.72

+0.80

+4.00%

4,032.60

-81.90

-1.99%

73,050.65

-1,923.38

-2.57%

Crude Oil Dec 26

86.68

-0.17

-0.20%

US Private Equity

10,850.15

0.00

0.00%

NasdaqCM - Nasdaq Real Time Price USD

Tempest Therapeutics, Inc. (TPST)

0.3520 -0.0097 (-2.68%)

As of 11:31:14 AM EST. Market Open.

Loading Chart for TPST

Chart Range Bar

Interval:

In partnership with ChartIQ

Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise

Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Mobilize your Website

View Site in Mobile | Classic

Share by: